PMID- 24019785
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130910
LR  - 20211021
IS  - 1662-6575 (Print)
IS  - 1662-6575 (Electronic)
IS  - 1662-6575 (Linking)
VI  - 6
IP  - 2
DP  - 2013
TI  - Prolonged clinical benefit of everolimus therapy in the management of high-grade 
      pancreatic neuroendocrine carcinoma.
PG  - 441-9
LID - 10.1159/000354754 [doi]
AB  - Treatment options for patients with high-grade pancreatic neuroendocrine tumors 
      (pNET) are limited, especially for those with progressive disease and for those 
      who experience treatment failure. Everolimus, an oral inhibitor of mammalian 
      target of rapamycin (mTOR), has been approved for the treatment of patients with 
      low- or intermediate-grade advanced pNET. In the randomized phase III RADIANT-3 
      study in patients with low- or intermediate-grade advanced pNET, everolimus 
      significantly increased progression-free survival (PFS) and decreased the 
      relative risk for disease progression by 65% over placebo. This case report 
      describes a heavily pretreated patient with high-grade pNET and liver and 
      peritoneal metastases who achieved prolonged PFS, clinically relevant partial 
      radiologic tumor response, and resolution of constitutional symptoms with 
      improvement in Karnofsky performance status while receiving a combination of 
      everolimus and octreotide long-acting repeatable (LAR). Radiologic and clinical 
      responses were maintained for 19 months, with minimal toxicity over the course of 
      treatment. This case supports the findings that the combination of everolimus 
      plus octreotide LAR may be considered for use in patients with high-grade pNET 
      and progressive disease. Although behavior and aggressiveness are different 
      between low- or intermediate-grade and high-grade pNET, some high-grade pNET may 
      express mTOR; hence, everolimus should be considered in a clinical trial.
FAU - Fonseca, Paula J
AU  - Fonseca PJ
AD  - Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, 
      Spain.
FAU - Uriol, Esther
AU  - Uriol E
FAU - Galvan, Jose A
AU  - Galvan JA
FAU - Alvarez, Carlos
AU  - Alvarez C
FAU - Perez, Quionia
AU  - Perez Q
FAU - Villanueva, Noemi
AU  - Villanueva N
FAU - Berros, Jose P
AU  - Berros JP
FAU - Izquierdo, Marta
AU  - Izquierdo M
FAU - Vieitez, Jose M
AU  - Vieitez JM
LA  - eng
PT  - Case Reports
DEP - 20130824
PL  - Switzerland
TA  - Case Rep Oncol
JT  - Case reports in oncology
JID - 101517601
PMC - PMC3764965
OTO - NOTNLM
OT  - Everolimus
OT  - Neuroendocrine tumors
OT  - Octreotide long-acting repeatable
OT  - Pancreatic
EDAT- 2013/09/11 06:00
MHDA- 2013/09/11 06:01
PMCR- 2013/08/24
CRDT- 2013/09/11 06:00
PHST- 2013/09/11 06:00 [entrez]
PHST- 2013/09/11 06:00 [pubmed]
PHST- 2013/09/11 06:01 [medline]
PHST- 2013/08/24 00:00 [pmc-release]
AID - cro-0006-0441 [pii]
AID - 10.1159/000354754 [doi]
PST - epublish
SO  - Case Rep Oncol. 2013 Aug 24;6(2):441-9. doi: 10.1159/000354754. eCollection 2013.